MAPK3 and Hepatic fibrosis: Therefore, Hugan tablets may inhibit the activation of the PI3K-Akt signaling pathway through IL-6, AKT1, VEGFA, EGFR, and MAPK3, thereby inhibiting the activation of HSCs and delaying the occurrence of liver fibrosis.